Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial.
about
Hodgkin lymphoma, version 2.2015.Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis.Role of chemotherapy in Hodgkin's lymphoma.Clinical features and treatment outcomes of Hodgkin's lymphoma in Hong Kong Chinese.Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patientsUtility of bone marrow biopsy at diagnosis in pediatric Hodgkin's lymphoma.Role of Radiotherapy in Modern Treatment of Hodgkin's LymphomaHodgkin's lymphoma therapy: past, present, and future.A Historical Tale of Two Lymphomas: Part I: Hodgkin lymphomaStage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience.Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group.Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin LymphomaThe Management of Classical Hodgkin's Lymphoma: Past, Present, and FutureThe benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapyLessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies.Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 TrialRadiation therapy compared with chemotherapy for consolidation of chemotherapy-induced remission of advanced Hodgkin lymphoma: a study by the Eastern Co-operative Oncology Group (E1476) with >20 years follow-upCurrent concepts and controversies in the management of early stage Hodgkin lymphoma.Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease.Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trialsLack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yieldCurrent strategies and new approaches in the treatment of Hodgkin's lymphoma.Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trialBrentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK centerClassical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-upMinimizing late effects in children and adults with Hodgkin lymphoma - the beginning of the end for radiation therapy.A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425.Hodgkin's lymphoma: current treatment strategies and novel approaches.PET Response-Guided Treatment of Hodgkin's Lymphoma: A Review of the Evidence and Active Clinical TrialsThe unique characteristics and management of patients over 60 years of age with classic Hodgkin lymphoma.State of the art in the treatment of Hodgkin lymphoma.High-dose therapy followed by stem cell transplantation in Hodgkin's lymphoma: past and future.The role of allogeneic stem cell transplantation in Hodgkin's lymphoma.The GHSG Approach to Treating Hodgkin's Lymphoma.Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.Does Radiation Have a Role in Advanced Stage Hodgkin's or Non-Hodgkin Lymphoma?Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans.Axillary swelling and a reduced general condition in a middle-aged man.PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
P2860
Q30769157-F348D5CF-1728-4767-9DC7-CDF33D8E0E7DQ33208378-54CB6433-3646-4DD6-A9D5-C739E1E9551EQ33761103-2A5FE429-CD3C-4FFF-8505-9AF44056A181Q33935351-F3C5CB49-73CD-4825-B884-8EB70664BA81Q34115831-A748D1F5-3E1A-48C2-B661-E3CCAB96F9C9Q34166545-88BF826E-A327-454D-A562-7E4FEF10BDD6Q34235785-277596C0-B919-4802-98FA-57A09445BFA9Q34296914-1966C07F-E9EE-4065-B9C3-6007FD0AE10DQ34479660-04B868ED-163B-438E-AF58-011A1B09110DQ34486551-2105587A-3D7B-4C61-BE7D-539947FB3F6FQ34645722-699C3EAC-BAD8-417C-9CC3-2EA2A31C4AB0Q34707420-105F9EC4-BDB3-4DA7-A4C3-7BF4325711D8Q35038832-301C7A3E-D0F6-469E-8B29-E6B77C9AE1EFQ35038852-F4C97161-6C46-4EE1-9FE0-B2A01457E4CEQ35219755-4384B96E-18AE-4BAB-90BB-3E73A93530E1Q35667279-8FB79881-AE02-47D2-A93A-5D1891EE7055Q35671369-78E051E8-F895-4952-8A87-39586411D37FQ35892254-41DC1503-508B-4267-B87F-2D9D6EC03C46Q36061643-A02F25C4-921C-4B42-AEF4-7BF09F2BE351Q36099062-1008FC61-FCD7-4594-A81C-7E3639B78257Q36589635-B4A70175-127F-40E1-99EF-F4F87B1D1801Q36614046-6037C336-503C-4595-A407-4D3B13D6BA34Q36645617-70C1753A-42E1-409A-BD39-FDF8C14CCD51Q36702397-3AD99112-CF4E-46CE-95BB-25AE14894BACQ36862523-4FBCE3F5-7871-4ECC-A65E-2036B376B402Q37146056-4AA54B2B-3B41-4B16-BF65-1C4AA29E6E8FQ37157419-C58826B1-4A29-4DD2-AC46-7E1950C1BCB2Q37348243-E734911F-9AFB-4061-AD16-DDD32D70EDE6Q37810114-ABED9E0C-8BF8-4A6B-9E83-F8F5DFA3F01DQ37828408-0FCEA922-F4C8-4CB4-8F40-31436D789E0EQ37873408-9DA8A74C-0771-4BAA-83BA-F2AFCB31B03BQ38017914-1F8F0546-4BE5-41A0-998A-AFD970541752Q38132819-500C3CD1-3639-4256-AC3D-5DA8506D57CFQ38206138-359140B9-F918-4F68-BCDA-086FCA87AD52Q38506223-A36D41AD-2514-4BDB-92E7-0E745D49059CQ38664909-6A213D1B-45D2-47C1-8440-6CFDBA510402Q38688797-24F12818-CFC2-4126-878B-2358F3E259B0Q40177374-5A796437-05DB-4C22-A8BC-EB432A5AFCFEQ40494938-017DC013-9873-4084-9F8F-EF576BC7C2C5Q41069147-91A94F54-29CC-47C6-A7C4-B12996A8ADFD
P2860
Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Stanford V and radiotherapy fo ...... a prospective clinical trial.
@ast
Stanford V and radiotherapy fo ...... a prospective clinical trial.
@en
Stanford V and radiotherapy fo ...... a prospective clinical trial.
@nl
type
label
Stanford V and radiotherapy fo ...... a prospective clinical trial.
@ast
Stanford V and radiotherapy fo ...... a prospective clinical trial.
@en
Stanford V and radiotherapy fo ...... a prospective clinical trial.
@nl
prefLabel
Stanford V and radiotherapy fo ...... a prospective clinical trial.
@ast
Stanford V and radiotherapy fo ...... a prospective clinical trial.
@en
Stanford V and radiotherapy fo ...... a prospective clinical trial.
@nl
P2093
P356
P1476
Stanford V and radiotherapy fo ...... a prospective clinical trial.
@en
P2093
B William Brown
Nancy L Bartlett
Richard T Hoppe
Sandra J Horning
Saul A Rosenberg
Sheila Breslin
P304
P356
10.1200/JCO.20.3.630
P407
P577
2002-02-01T00:00:00Z